Joung‐Liang Lan

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.

Der‐Yuan Chen, Joung‐Liang Lan, Fang‐Ju Lin et al. · PubMed · 2004 · 260 citations

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

Der‐Yuan Chen, Yi‐Ming Chen, Hsin‐Hua Chen et al. · Arthritis Research & Therapy · 2011 · 207 citations · Full text

Dehydroepiandrosterone treatment of women with mild‐to‐moderate systemic lupus erythematosus: A multicenter randomized, double‐blind, placebo‐controlled trial

Deh‐Ming Chang, Joung‐Liang Lan, Hsiao‐Yi Lin et al. · Arthritis & Rheumatism · 2002 · 163 citations · Full text

Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study

Yi‐Ming Chen, Ching‐Heng Lin, Tsuo‐Hung Lan et al. · Lara D. Veeken · 2015 · 130 citations · Full text